3.1 Our Team

Our Leadership Team

Eric Lefkofsky Founder & CEO

Read Bio

Nike Beaubier, MD Vice President, Head of Translational Medicine

Read Bio

Shane Colley Chief Technology Officer

Read Bio

Joel Dudley, PhD Senior Vice President of Research

Read Bio

Colette Freeman Chief People Officer

Read Bio

Ryan Fukushima Chief Operating Officer

Read Bio

Kim Blackwell, MD Chief Medical Officer

Read Bio

Erik Phelps Chief Administrative and Legal Officer

Read Bio

Vanessa Rollings Chief Financial Officer

Read Bio

Martin Stumpe, PhD Senior Vice President of Data Science

Read Bio

Gary Palmer, MD SVP of Medical Affairs

Read Bio

Lauren Silvis Senior Vice President of External Affairs

Read Bio

Eric Singley Vice President of Product

Read Bio

Kevin White, PhD Chief Science Officer

Read Bio

Mike Yasiejko Chief Commercial Officer

Read Bio

Kimberly Yeatts Vice President of Clinical Lab Operations

Read Bio

Marc Yoskowitz Chief Strategy Officer

Read Bio

Andy Polovin General Counsel

Read Bio

Ari Caroline Senior Vice President of Health Strategy

Read Bio

Christopher Mason Vice President of Emerging Genome Technology

Read Bio

Our Scientific Advisors

David Agus, MD Scientific Advisor

Read Bio

Arul Chinnaiyan, MD, PhD Scientific Advisor

Read Bio

Funmi Olopade, MD Scientific Advisor

Read Bio

A. Keith Stewart, MB.ChB., MBA Scientific Advisor

Read Bio

Eric Topol, MD Scientific Advisor

Read Bio

Some Other Advisors

“We are thrilled to have led an investment in Tempus... Given NEA's long and successful history investing in the intersection of technology and life science, we felt like the perfect strategic partner given Tempus' mission to help doctors personalize care by collecting and analyzing large volumes of data.”

Peter Barris, Chairman & General Partner, New Enterprise Associates

“Having spent my entire career at the forefront of emerging technologies, it’s exciting to see how healthcare is finally embracing the very technologies that have transformed so many other industries. This is a space that is near and dear to me, and I'm excited to be a part of Tempus as they seek to bring big data, artificial intelligence and advanced molecular analysis to those suffering with cancer and other life threatening diseases.”

Ted Leonsis, Cofounder & Partner, Revolution Growth

“Nowhere is technology more desperately needed than in healthcare. As a country, we spend over three trillion dollars annually. We have a social and economic imperative to improve our healthcare system: to make it better, more accessible, and more effective. I'm thrilled to have invested in Tempus and their team of innovators who are obsessed with developing breakthroughs in how we treat diseases.”

John Doerr, Chairman, Kleiner Perkins